|Elimination Half-life||9 to 13 Hours (aprepitant)|
Preferred Buyer From
|Location||All Countries Except India|
Fosaprepitant is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration on January 25, 2008 and by the European Medicines Agency on January 11 of the same year.